AlconALC
Market Cap: $46.7B
About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Employees: 25,315
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
28% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 58
24% more call options, than puts
Call options by funds: $224M | Put options by funds: $181M
16% more capital invested
Capital invested by funds: $19.4B [Q1] → $22.5B (+$3.11B) [Q2]
3.75% more ownership
Funds ownership: 47.44% [Q1] → 51.19% (+3.75%) [Q2]
3% more funds holding
Funds holding: 600 [Q1] → 616 (+16) [Q2]
4% less repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 209
7% less funds holding in top 10
Funds holding in top 10: 15 [Q1] → 14 (-1) [Q2]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Wells Fargo Larry Biegelsen 68% 1-year accuracy 25 / 37 met price target | 11%upside $105 | Overweight Maintained | 22 Aug 2024 |
Oppenheimer Steven Lichtman 72% 1-year accuracy 13 / 18 met price target | 16%upside $110 | Outperform Maintained | 22 Aug 2024 |
BTIG Ryan Zimmerman 56% 1-year accuracy 19 / 34 met price target | 4%upside $98 | Buy Maintained | 22 Aug 2024 |
Baird Jeff Johnson 58% 1-year accuracy 7 / 12 met price target | 16%upside $110 | Outperform Maintained | 22 Aug 2024 |
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target | 13%upside $107 | Buy Maintained | 22 Aug 2024 |
Financial journalist opinion
Based on 8 articles about ALC published over the past 30 days